Double-Blinded, Placebo Controlled Study Evaluating the Safety and Efficacy of Intravenous Allogeneic Adipose Stromal Cell Therapy for Canine Osteoarthritis

ABSTRACT The objective of this study was to provide preliminary data describing the safety and effect of cannabidiol (CBD) for symptom relief of canine osteoarthritis-associated pain in a clinical setting using objective outcome measures. Twenty-three client-owned dogs with naturally occurring osteoarthritis of appendicular joints completed this prospective, double-blinded, crossover, placebo-controlled study. Baseline data were acquired for 4 wk, followed by random allocation to either placebo or CBD treatment for 6 wk, followed by 6 wk with the opposite treatment. Outcome measures included objective gait analysis, activity counts (via accelerometry) and clinical metrology instruments. There were no differences noted between groups at any time point for any of the recorded outcome measures. Adverse events associated with CBD administration included elevation in liver enzymes (n = 14) and vomiting (n = 2).

Download Full-text

Adipose Stromal Cell Therapy for Cardiovascular Disease

Handbook of Cardiovascular Cell Transplantation ◽

10.3109/9780203640685-23 ◽

2003 ◽

pp. 305-309

Author(s):

Jalees Rehman ◽

Keith March

Keyword(s):

Cardiovascular Disease ◽

Cell Therapy ◽

Stromal Cell ◽

Adipose Stromal Cell

Download Full-text

Safety and Efficacy of Ferula asafoetida in Functional Dyspepsia: A Randomized, Double-Blinded, Placebo-Controlled Study

Evidence-based Complementary and Alternative Medicine ◽

10.1155/2018/4813601 ◽

2018 ◽

Vol 2018 ◽

pp. 1-11 ◽

Cited By ~ 4

Author(s):

K. N. Mala ◽

Jestin Thomas ◽

Das S. Syam ◽

Balu Maliakel ◽

I. M. Krishnakumar

Keyword(s):

Functional Dyspepsia ◽

Group Versus ◽

Controlled Study ◽

Present Contribution ◽

Safety And Efficacy ◽

Postprandial Fullness ◽

Synthetic Drugs ◽

Hard Shell ◽

Double Blinded ◽

Ferula Asafoetida

Despite the availability of various synthetic drugs for the treatment of functional dyspepsia (FD), the side effects and their cost have always created a great interest in the search for novel natural alternatives for the management of gut disorders. The present contribution reports the safety and efficacy of the kitchen spice asafoetida (Ferula asafoetida) in FD for the first time. In the double-blinded, placebo-controlled study, 43 subjects diagnosed to have moderate to severe discomforts of nonulcer FD were randomized to receive hard-shell capsules (250 mg × 2/day) of either placebo (n=22) or a food-grade formulation of asafoetida (Asafin) (n=21) for 30 days. When evaluated by a set of validated indexing tools (GSRS, GDSS, and NDI), almost 81% in the Asafin group showed significant (p < 0.01) improvement in the overall score and quality of life as compared to the placebo. At the end of the study, 66% of subjects in the Asafin group remained symptoms-free. Although the symptoms score improved significantly in both the groups (from -5.67 to -25.29 in Asafin group versus -1.55 to -6.0 in the placebo; p ≤ 0.001), the relative percentage of subjects in the Asafin group with more than 80% reduction in various symptoms were: bloating (58%), appetite (69%), postprandial fullness (74%) motion sickness (75%), and digestion (77%) as compared to less than 10% nonspecific improvement in the placebo group. All the subjects remained safe with no adverse events or variations in haematological and biochemical parameters. The study was registered at http://ctri.nic.in/ (CTRI/2018/ 01/011149).

Download Full-text

Safety and Efficacy of Intravenous Zanamivir in Preventing Experimental Human Influenza A Virus Infection

Antimicrobial Agents and Chemotherapy ◽

10.1128/aac.43.7.1616 ◽

1999 ◽

Vol 43 (7) ◽

pp. 1616-1620 ◽

Cited By ~ 90

Author(s):

David P. Calfee ◽

Amy W. Peng ◽

Lindsey M. Cass ◽

Monica Lobo ◽

Frederick G. Hayden

Keyword(s):

Influenza A Virus ◽

Influenza A ◽

Controlled Study ◽

Nasal Discharge ◽

Upper Respiratory Tract ◽

Human Influenza ◽

Safety And Efficacy ◽

Viral Shedding ◽

Respiratory Tract Illness ◽

Double Blinded

ABSTRACT Zanamivir is a potent inhibitor of influenza A and B virus neuraminidases and is active topically in experimental and natural human influenza. We conducted this double-blinded, placebo-controlled study to evaluate the safety and efficacy of intravenously administered zanamivir. Susceptible volunteers were randomized to receive either saline or zanamivir (600 mg) intravenously twice daily for 5 days beginning 4 h prior to intranasal inoculation with ∼105 50% tissue culture infectious doses (TCID50) of influenza A/Texas/36/91 (H1N1) virus. Reductions in the frequency of viral shedding (0% versus 100% in placebo, P < 0.005) and seroconversion (14% versus 100% in placebo, P < 0.005) and decreases in viral titer areas under the curve (0 versus 11.6 [median] log10 TCID50 · day/ml in placebo,P < 0.005) were observed in the zanamivir group, as were reductions in fever (14% versus 88% in placebo,P < 0.05), upper respiratory tract illness (0% versus 100% in placebo, P < 0.005), total symptom scores (1 versus 44 [median] in placebo, P < 0.005), and nasal-discharge weight (3.9 g versus 17.5 g [median] in placebo, P < 0.005). Zanamivir was detectable in nasal lavage samples collected on days 2 and 4 (unadjusted median concentrations, 10.5 and 12.0 ng/ml of nasal wash, respectively). This study demonstrates that intravenously administered zanamivir is distributed to the respiratory mucosa and is protective against infection and illness following experimental human influenza A virus inoculation.

Download Full-text